^
Association details:
| Biomarker: | ATM deletion |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | berzosertib (M6620) (ATR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer
Published date:
11/22/2023
Excerpt:
We tested the differential sensitivity of ATM-deleted versus WT ATM bladder cancer cell lines to the ATR inhibitor berzosertib. In nearly all ATM-deleted cell lines tested, there was a significant increase in ATR inhibitor sensitivity relative to WT ATM cells...
DOI:
10.1126/sciadv.adg2263
